Cargando…

Development and Evaluation of Single Domain Antibodies for Vaccinia and the L1 Antigen

There is ongoing interest to develop high affinity, thermal stable recognition elements to replace conventional antibodies in biothreat detection assays. As part of this effort, single domain antibodies that target vaccinia virus were developed. Two llamas were immunized with killed viral particles...

Descripción completa

Detalles Bibliográficos
Autores principales: Walper, Scott A., Liu, Jinny L., Zabetakis, Daniel, Anderson, George P., Goldman, Ellen R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161341/
https://www.ncbi.nlm.nih.gov/pubmed/25211488
http://dx.doi.org/10.1371/journal.pone.0106263
_version_ 1782334535295303680
author Walper, Scott A.
Liu, Jinny L.
Zabetakis, Daniel
Anderson, George P.
Goldman, Ellen R.
author_facet Walper, Scott A.
Liu, Jinny L.
Zabetakis, Daniel
Anderson, George P.
Goldman, Ellen R.
author_sort Walper, Scott A.
collection PubMed
description There is ongoing interest to develop high affinity, thermal stable recognition elements to replace conventional antibodies in biothreat detection assays. As part of this effort, single domain antibodies that target vaccinia virus were developed. Two llamas were immunized with killed viral particles followed by boosts with the recombinant membrane protein, L1, to stimulate the immune response for envelope and membrane proteins of the virus. The variable domains of the induced heavy chain antibodies were selected from M13 phage display libraries developed from isolated RNA. Selection via biopanning on the L1 antigen produced single domain antibodies that were specific and had affinities ranging from 4×10(−9) M to 7.0×10(−10) M, as determined by surface plasmon resonance. Several showed good ability to refold after heat denaturation. These L1-binding single domain antibodies, however, failed to recognize the killed vaccinia antigen. Useful vaccinia binding single domain antibodies were isolated by a second selection using the killed virus as the target. The virus binding single domain antibodies were incorporated in sandwich assays as both capture and tracer using the MAGPIX system yielding limits of detection down to 4×10(5) pfu/ml, a four-fold improvement over the limit obtained using conventional antibodies. This work demonstrates the development of anti-vaccinia single domain antibodies and their incorporation into sandwich assays for viral detection. It also highlights the properties of high affinity and thermal stability that are hallmarks of single domain antibodies.
format Online
Article
Text
id pubmed-4161341
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41613412014-09-17 Development and Evaluation of Single Domain Antibodies for Vaccinia and the L1 Antigen Walper, Scott A. Liu, Jinny L. Zabetakis, Daniel Anderson, George P. Goldman, Ellen R. PLoS One Research Article There is ongoing interest to develop high affinity, thermal stable recognition elements to replace conventional antibodies in biothreat detection assays. As part of this effort, single domain antibodies that target vaccinia virus were developed. Two llamas were immunized with killed viral particles followed by boosts with the recombinant membrane protein, L1, to stimulate the immune response for envelope and membrane proteins of the virus. The variable domains of the induced heavy chain antibodies were selected from M13 phage display libraries developed from isolated RNA. Selection via biopanning on the L1 antigen produced single domain antibodies that were specific and had affinities ranging from 4×10(−9) M to 7.0×10(−10) M, as determined by surface plasmon resonance. Several showed good ability to refold after heat denaturation. These L1-binding single domain antibodies, however, failed to recognize the killed vaccinia antigen. Useful vaccinia binding single domain antibodies were isolated by a second selection using the killed virus as the target. The virus binding single domain antibodies were incorporated in sandwich assays as both capture and tracer using the MAGPIX system yielding limits of detection down to 4×10(5) pfu/ml, a four-fold improvement over the limit obtained using conventional antibodies. This work demonstrates the development of anti-vaccinia single domain antibodies and their incorporation into sandwich assays for viral detection. It also highlights the properties of high affinity and thermal stability that are hallmarks of single domain antibodies. Public Library of Science 2014-09-11 /pmc/articles/PMC4161341/ /pubmed/25211488 http://dx.doi.org/10.1371/journal.pone.0106263 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Walper, Scott A.
Liu, Jinny L.
Zabetakis, Daniel
Anderson, George P.
Goldman, Ellen R.
Development and Evaluation of Single Domain Antibodies for Vaccinia and the L1 Antigen
title Development and Evaluation of Single Domain Antibodies for Vaccinia and the L1 Antigen
title_full Development and Evaluation of Single Domain Antibodies for Vaccinia and the L1 Antigen
title_fullStr Development and Evaluation of Single Domain Antibodies for Vaccinia and the L1 Antigen
title_full_unstemmed Development and Evaluation of Single Domain Antibodies for Vaccinia and the L1 Antigen
title_short Development and Evaluation of Single Domain Antibodies for Vaccinia and the L1 Antigen
title_sort development and evaluation of single domain antibodies for vaccinia and the l1 antigen
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161341/
https://www.ncbi.nlm.nih.gov/pubmed/25211488
http://dx.doi.org/10.1371/journal.pone.0106263
work_keys_str_mv AT walperscotta developmentandevaluationofsingledomainantibodiesforvacciniaandthel1antigen
AT liujinnyl developmentandevaluationofsingledomainantibodiesforvacciniaandthel1antigen
AT zabetakisdaniel developmentandevaluationofsingledomainantibodiesforvacciniaandthel1antigen
AT andersongeorgep developmentandevaluationofsingledomainantibodiesforvacciniaandthel1antigen
AT goldmanellenr developmentandevaluationofsingledomainantibodiesforvacciniaandthel1antigen